57 research outputs found
Mechanisms for Vascular Cell Adhesion Molecule-1 Activation of ERK1/2 during Leukocyte Transendothelial Migration
Background: During inflammation, adhesion molecules regulate recruitment of leukocytes to inflamed tissues. It is reported that vascular cell adhesion molecule-1 (VCAM-1) activates extracellular regulated kinases 1 and 2 (ERK1/2), but the mechanism for this activation is not known. Pharmacological inhibitors of ERK1/2 partially inhibit leukocyte transendothelial migration in a multi-receptor system but it is not known whether VCAM-1 activation of ERK1/2 is required for leukocyte transendothelial migration (TEM) on VCAM-1. Methodology/Principal Findings: In this study, we identified a mechanism for VCAM-1 activation of ERK1/2 in human and mouse endothelial cells. VCAM-1 signaling, which occurs through endothelial cell NADPH oxidase, protein kinase Ca (PKCa), and protein tyrosine phosphatase 1B (PTP1B), activates endothelial cell ERK1/2. Inhibition of these signals blocked VCAM-1 activation of ERK1/2, indicating that ERK1/2 is activated downstream of PTP1B during VCAM-1 signaling. Furthermore, VCAM-1-specific leukocyte migration under physiological laminar flow of 2 dynes/cm 2 was blocked by pretreatment of endothelial cells with dominant-negative ERK2 K52R or the MEK/ERK inhibitors, PD98059 and U0126, indicating for the first time that ERK regulates VCAM-1-dependent leukocyte transendothelial migration. Conclusions/Significance: VCAM-1 activation of endothelial cell NADPH oxidase/PKCa/PTP1B induces transient ERK1/2 activation that is necessary for VCAM-1-dependent leukocyte TEM
Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive UltrasoundĆ¢ Guided Synovial Biopsies in Rheumatoid Arthritis
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144312/1/art40453_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/144312/2/art40453.pd
IMPLICATION DES PHOSPHOLIPASES A2 DE LEISHMANIA DANS L'INVASION ET LA SURVIE (CIBLE POTENTIELLE DE DERIVES DE LA 2-AMINO-4,6-DIMETHYLPYRIDINE)
NANTES-BU MĆ©decine pharmacie (441092101) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF
Vitamin E Isoforms as Modulators of Lung Inflammation
Asthma and allergic diseases are complex conditions caused by a combination of genetic and environmental factors. Clinical studies suggest a number of protective dietary factors for asthma, including vitamin E. However, studies of vitamin E in allergy commonly result in seemingly conflicting outcomes. Recent work indicates that allergic inflammation is inhibited by supplementation with the purified natural vitamin E isoform Ī±-tocopherol but elevated by the isoform Ī³-tocopherol when administered at physiological tissue concentrations. In this review, we discuss opposing regulatory effects of Ī±-tocopherol and Ī³-tocopherol on allergic lung inflammation in clinical trials and in animal studies. A better understanding of the differential regulation of inflammation by isoforms of vitamin E provides a basis towards the design of clinical studies and diets that would effectively modulate inflammatory pathways in lung disease
Vitamin E isoforms differentially regulate intercellular adhesion molecule-1 activation of PKCĪ± in human microvascular endothelial cells.
ICAM-1-dependent leukocyte recruitment in vivo is inhibited by the vitamin E isoform d-Ī±-tocopherol and elevated by d-Ī³-tocopherol. ICAM-1 is reported to activate endothelial cell signals including protein kinase C (PKC), but the PKC isoform and the mechanism for ICAM-1 activation of PKC are not known. It is also not known whether ICAM-1 signaling in endothelial cells is regulated by tocopherol isoforms. We hypothesized that d-Ī±-tocopherol and d-Ī³-tocopherol differentially regulate ICAM-1 activation of endothelial cell PKC.ICAM-1 crosslinking activated the PKC isoform PKCĪ± but not PKCĪ² in TNFĪ±-pretreated human microvascular endothelial cells. ICAM-1 activation of PKCĪ± was blocked by the PLC inhibitor U73122, ERK1/2 inhibitor PD98059, and xanthine oxidase inhibitor allopurinol. ERK1/2 activation was blocked by inhibition of XO and PLC but not by inhibition of PKCĪ±, indicating that ERK1/2 is downstream of XO and upstream of PKCĪ± during ICAM-1 signaling. During ICAM-1 activation of PKCĪ±, the XO-generated ROS did not oxidize PKCĪ±. Interestingly, d-Ī±-tocopherol inhibited ICAM-1 activation of PKCĪ± but not the upstream signal ERK1/2. The d-Ī±-tocopherol inhibition of PKCĪ± was ablated by the addition of d-Ī³-tocopherol.Crosslinking ICAM-1 stimulated XO/ROS which activated ERK1/2 that then activated PKCĪ±. ICAM-1 activation of PKCĪ± was inhibited by d-Ī±-tocopherol and this inhibition was ablated by the addition of d-Ī³-tocopherol. These tocopherols regulated ICAM-1 activation of PKCĪ± without altering the upstream signal ERK1/2. Thus, we identified a mechanism for ICAM-1 activation of PKC and determined that d-Ī±-tocopherol and d-Ī³-tocopherol have opposing regulatory functions for ICAM-1-activated PKCĪ± in endothelial cells
Comparative Study of SARS-CoV-2, SARS-CoV-1, MERS-CoV, HCoV-229E and Influenza Host Gene Expression in Asthma: Importance of Sex, Disease Severity, and Epithelial Heterogeneity
Epithelial characteristics underlying the differential susceptibility of chronic asthma to SARS-CoV-2 (COVID-19) and other viral infections are currently unclear. By revisiting transcriptomic data from patients with Th2 low versus Th2 high asthma, as well as mild, moderate, and severe asthmatics, we characterized the changes in expression of human coronavirus and influenza viral entry genes relative to sex, airway location, and disease endotype. We found sexual dimorphism in the expression of SARS-CoV-2-related genes ACE2, TMPRSS2, TMPRSS4, and SLC6A19. ACE2 receptor downregulation occurred specifically in females in Th2 high asthma, while proteases broadly assisting coronavirus and influenza viral entry, TMPRSS2, and TMPRSS4, were highly upregulated in both sexes. Overall, changes in SARS-CoV-2-related gene expression were specific to the Th2 high molecular endotype of asthma and different by asthma severity and airway location. The downregulation of ACE2 (COVID-19, SARS) and ANPEP (HCoV-229E) viral receptors wascorrelated with loss of club and ciliated cells in Th2 high asthma. Meanwhile, the increase in DPP4 (MERS-CoV), ST3GAL4, and ST6GAL1 (influenza) was associated with increased goblet and basal activated cells. Overall, this study elucidates sex, airway location, disease endotype, and changes in epithelial heterogeneity as potential factors underlying asthmatic susceptibility, or lack thereof, to SARS-CoV-2
Ubiquinone Synthesis in Mitochondrial and Microsomal Subcellular Fractions of Pneumocystis spp.: Differential Sensitivities to Atovaquone
The lung pathogen Pneumocystis spp. is the causative agent of a type of pneumonia that can be fatal in people with defective immune systems, such as AIDS patients. Atovaquone, an analog of ubiquinone (coenzyme Q [CoQ]), inhibits mitochondrial electron transport and is effective in clearing mild to moderate cases of the infection. Purified rat-derived intact Pneumocystis carinii cells synthesize de novo four CoQ homologs, CoQ(7), CoQ(8), CoQ(9), and CoQ(10), as demonstrated by the incorporation of radiolabeled precursors of both the benzoquinone ring and the polyprenyl chain. A central step in CoQ biosynthesis is the condensation of p-hydroxybenzoic acid (PHBA) with a long-chain polyprenyl diphosphate molecule. In the present study, CoQ biosynthesis was evaluated by the incorporation of PHBA into completed CoQ molecules using P. carinii cell-free preparations. CoQ synthesis in whole-cell homogenates was not affected by the respiratory inhibitors antimycin A and dicyclohexylcarbodiimide but was diminished by atovaquone. Thus, atovaquone has inhibitory activity on both electron transport and CoQ synthesis in this pathogen. Furthermore, both the mitochondrial and microsomal fractions were shown to synthesize de novo all four P. carinii CoQ homologs. Interestingly, atovaquone inhibited microsomal CoQ synthesis, whereas it had no effect on mitochondrial CoQ synthesis. This is the first pathogenic eukaryotic microorganism in which biosynthesis of CoQ molecules from the initial PHBA:polyprenyl transferase reaction has been unambiguously shown to occur in two distinct compartments of the same cell
Mechanisms for VCAM-1 activation of ERK1/2 in HMVEC-L.
<p>Treatment of HMVEC-L cells overnight with 10ng/ml TNF-Ī± induced VCAM-1 expression (data not shown). <b>A</b>) Confluent monolayers of TNF-Ī±-treated HMVEC-Ls were nontreated (NT) or treated with 27 Āµg/ml anti-VCAM-1 plus 15 Āµg/ml of a secondary antibody to crosslink and stimulate VCAM-1. Phosphorylation of ERK1/2 Thr202/Tyr204 (P-ERK1/2) and total expression of ERK1/2 was examined by western blot using rabbit anti-phospho ERK1/2 Thr202/Tyr204 (1/1000) followed by HRP-conjugated anti-rabbit (1/2000) and ECL detection. <b>B</b>) Confluent monolayers of TNF-Ī± stimulated HMVEC-L cells in 12 well plates were nontreated or incubated for 30 minutes with the solvent control DMSO, apocynin (4 mM), Gƶ-6976 (2.3 nM) or CinnGEL 2-methylester (10 ĀµM). These endothelial cells were then stimulated with anti-VCAM-1 antibody plus a secondary antibody for 15 minutes. The apocynin, DMSO, Gƶ-6976 or CinnGEL 2-methylester had no effect on endothelial cell viability as determined by trypan blue exclusion and had no effect on VCAM-1 expression as determined by flow cytometry (data not shown). Representative western blots are shown. Data presented are the mean Ā± standard deviation from 3 experiments. The phosphorylation status of ERK1/2 is presented as the fold increase in the ratio of the relative intensity of P-ERK1/2 divided by the relative intensity of the loading control (total ERK1/2). *, p<0.05 compared to <b>A</b>) NT cells or <b>B</b>) anti-VCAM-1 stimulated cells.</p
D-Ī±-tocopherol inhibits ICAM-1-activated PKCĪ± but not ERK1/2 in HMVECLs and the inhibition by d-Ī±-tocopherol is abrogated by d-Ī³-tocopherol.
<p>At 70% confluence, HMVECLs cells were pretreated with TNFĪ± for 6hrs and then treated with tocopherols or the solvent control 0.01% DMSO for 16 hrs. <b>A</b>) d-Ī±-tocopherol (Ī±-toc) regulation of ICAM-1-stimulated PKCĪ± Thr<sup>638</sup> phosphorylation (PKCĪ± P-Thr<sup>638</sup>). <b>B</b>) d-Ī³-tocopherol (Ī³-toc) regulation of ICAM-1-stimulated PKCĪ± P-Thr<sup>638</sup>. <b>C</b>) d-Ī±-tocopherol + d-Ī³-tocopherol regulation of ICAM-1-stimulated PKCĪ± P-Thr<sup>638</sup>. <b>D</b>) d-Ī±-tocopherol does not alter background PKCĪ± P-Thr<sup>638</sup> (no anti-ICAM-1). <b>E</b>) d-Ī±-tocopherol does not regulate ERK1/2 Thr<sup>202</sup>/Tyr<sup>204</sup> phosphorylation (P-ERK1/2). <b>F</b>) d-Ī³-tocopherol does not regulate ERK1/2 Thr<sup>202</sup>/Tyr<sup>204</sup> phosphorylation. Shown are the means Ā± SEM from 3 experiments. *, p<0.05 as compared with the anti-ICAM-1-stimulated groups.</p
- ā¦